<DOC>
	<DOCNO>NCT01854840</DOCNO>
	<brief_summary>Primary purpose : study relationship betamethasone placental transfer occurrence severity Hyaline Membrane Disease .</brief_summary>
	<brief_title>Betamethasone Severity Hyaline Membrane Disease</brief_title>
	<detailed_description>β-Mhyalines prospective multicentric non interventional study . One hundred fifty pregnant woman risk premature delivery , framework Hyaline Membrane Disease neonate , receive 2 intramuscular injection Celesten ( betamethasone ) 24 hour interval . Plasma sample collect : 2 mother delivery , one maternal one cord sample delivery . Concentrations measure analyzed use population approach . A ratio neonatal maternal exposure calculate represent placental transfer . The effect covariates ( genetic polymorphism CYP3A4 , CYP3A5 , P-glycoprotein… , others variables gestational age , bodyweight birth , apgar score , co-medication , maternal disease ) test explain variability placental transfer . The relationship placental transfer occurrence severity Hyaline Membrane Disease study , order target betamethasone maternal concentration thus optimize antenatal dose administer mother framework Hyaline Membrane Disease .</detailed_description>
	<mesh_term>Hyaline Membrane Disease</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>Pregnant woman receive least first injection Celesten prevention MMH . A oneterm &gt; 27 SA , Major Patients &gt; = 18 year old Informed Consent Form sign Patients undergoing treatment corticosteroid long term</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hyaline membrane disease</keyword>
	<keyword>placenta</keyword>
	<keyword>betamethasone</keyword>
</DOC>